The “up-and-coming diet drug” Viking (VKTX.US) drug enters the late stages of development, and the “Nolie” stock price fell in shock
As the Viking diet pill entered the later stages of clinical trials, Eli Lilly and Novo Nordisk stock prices declined.
Express News | Altimmune Inc: Weekly Subcutaneous Doses of Pemvidutide Resulted in up to 68.5% Relative Reduction in Liver Fat Content
Express News | Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (Masld) in Journal of Hepatology
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk
